DoH Equality policies screened 1 October to 31 December 2015
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- The Review of Pharmacy Regulation in Northern Ireland
- NICE (Clinical) Guideline NG17 - Type 1 diabetes in adults: diagnosis and management - This guideline updates and replaces the sections for adults in NICE guideline CG15
- NICE (Clinical) Guideline NG18 - Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE (Clinical) Guideline NG19 - Diabetic foot problems: prevention and management - This guideline updates and replaces NICE guidelines CG10 and CG119, and the recommendations on foot care in NICE guideline CG15
- NICE (Clinical) Guideline NG20 - Coeliac disease: recognition, assessment and management -This guideline updates and replaces NICE guideline CG86
- Extending the scope of the Direct Payments scheme to include individuals who lack the capacity to consent
- Changes to the entitlements of members of Committees
- Removal of the ban on the sale of HIV self-testing kits directly to the public in Northern Ireland
- Implementation of the EU Tobacco Products Directive (TPD) (Directive 2014/40/EU)
- Medicines Optimisation Quality Framework
- NICE Technology Appraisal TA355 - Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
- NICE Technology Appraisal TA 357 - Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab
- NICE Technology Appraisal TA358 - Tolvaptan for treating autosomal dominant polycystic kidney disease
- NICE Technology Appraisal TA359 - Idelalisib for previously treated chronic lymphocytic leukaemia
- NICE Technology Appraisal TA360 - Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
- NICE Technology Appraisal TA363 - Ledipasvir-sofosbuvir for treating chronic hepatitis C
- NICE Technology Appraisal TA364 - Daclatasvir for treating chronic hepatitis
- NICE Technology Appraisal - TA 365 - Ombitasvir/paritaprevir/ritonavir with or without dasabuvir for treating chronic hepatitis C
- NICE Technology Appraisal TA 366 - Pembrolizumab for treating advanced melanoma previously untreated with ipilimumab
- NICE Technology Appraisal TA 367 - Vortioxetine for treating major depressive disorder
- NICE Technology Appraisal NICE TA368 - Apremilast for treating moderate to severe plaque psoriasis